Since there is an overall augmentation of sympathetic nervous activity in patients with congestive heart failure while adrenal medullary function is normal and neurotransmitter stores are diminished in the heart, investigation was directed to the functional status of adrenergic receptors and available norepinephrine stores in the peripheral vascular beds. Blood flow, determined plethysmographically, and vascular resistance, calculated in the calf, following intra-arterial injections of tyramine and norepinephrine in eight patients with congestive heart failure were compared to the responses in nine patients with heart disease but without heart failure. The absolute increase in vascular resistance produced by graded doses of norepinephrine was greater in patients with heart failure. However, the relative augmentation of vascular resistance produced by any dose of norepinephrine was essentially identical in the two groups. In contrast, the vasoconstrictor response to a standard dose of the indirectly acting sympathomimetic agent, tyramine, was markedly enhanced (P < 0.01) in cases of heart failure, both when this increased response was considered in terms of the relative rise in vascular resistance, and in the quantity of injected norepinephrine required to produce a similar elevation of resistance. Concentration of norepinephrine in atrial tissue, determined at the time of cardiac surgery a few days after completion of the pharmacological studies, was significantly lower in the patients with heart failure. It is concluded that the quantity of endogenous sympathetic neurotransmitter available for release by tyramine from nerve endings in the peripheral arteriolar bed in the calf is not reduced and may even be augmented in patients with heart failure, and that the elevated levels of plasma norepinephrine in the heart failure state are derived, at least in part, from labile adrenergic stores in the peripheral vascular bed.
T HERE IS NOW considerable evidence that sympathetic activity is augmented in patients with congestive heart failure. 1 Hg/ml/ 100 g/min, was significantly higher (P <0.01). In these patients the standard dose of tyramine produced a maximal elevation of calf vascular resistance of 39.2+± 4.5 mm Hg/ml/100 g/min to 84.4 + 9.8 mm Hg/ ml/100 g/min, a rise that was significantly greater, both absolutely and relatively (P < 0.01), than that observed in the patients in group I ( fig. 1 ). While the absolute increase of vascular resistance in response to each dose of norepinephrine was significantly greater than in the patients in group I, the relative increases did not differ in the two groups.
The injection of the standard dose of tyramine (100 yg/m2 BSA) resulted in an increase in vascular resistance which was, on the average, similar to that resulting from the injection of 0.25 ,Ug/m2 BSA of norepinephrine ( fig. 1) Figure 2 Norepinephrine dose-response curves for the two groups of patients, with response expressed exponentially as the mean per cent increment above basal calf vascular resistance (CVR) produced by graded doses of norepinephrine (NE). The resultant overlapping suggests a fundamental similarity of arteriolar response to exogenous norepinephrine among the two groups of patients. In contrast, the mean per cent increment of calf vascular resistance after tyramine injection was significantly greater in the heart failure group (inset).
significance of this response was expressed in terms of the "norepinephrine-equivalent dose." This was accomplished by determining the dose of norepinephrine which had to be injected in order to produce an effect similar to that produced by the standard dose of tyramine. The response of calf vascular resistance to tyramine for each group of patients was placed on the appropriate norepinephrine dose-response curve, and it was calculated that the norepinephrine-equivalent dose for tyramine (100 11g/m2) for patients without heart failure was significantly less (P < 0.01) than for patients with heart failure ( fig. 1) .
The absolute levels of vascular resistance in the two groups of patients in the control period differed from one another, and the relative effects of various doses of norepinephrine, expressed as the per cent increment of calf vascular resistance above control levels were determined and found to be essentially identical in the two groups of patients ( fig. 2) . In contrast, the relative increments of vascular resistance elicited by the standard dose of tyramine differed greatly and averaged 19 + 1.0% in patients in group I and 87 ± 1.5% in patients with heart failure.
Concentration of Norepinephrine in Cardiac Tissue
In the six patients in group I in whom atrial tissue was obtained, the concentration of norepinephrine in the atrium averaged 1.54 + 0.26 ,/g/g. This was significantly lower (P < 0.01) than the concentration in the eight patients in group II, in whom it averaged 0.30 + 0.06 ug/g ( fig. 3) .
Discussion
Blood flow in the lower extremities was lower and vascular resistance higher in the patients with heart failure than in the patients with heart disease without functional impairment ( fig. 1) . The heart failure state is believed to produce increased peripheral vascular resistance,1' 7presumably by arteriolar constriction due to augmented activity of the sympathetic constrictor nerves,1 2, 9, 10 and by altering directly the mechanical properties of the vessel wall.1" In addition, the absolute increase in resistance produced by any given dose of norepinephrine was greater in patients with heart failure ( fig. 1) XXXVIII, October 1968 that the quantity of endogenous sympathetic neurotransmitter available for release by tyramine from nerve endings in the peripheral vascular bed is not reduced and may actually be appreciably increased in chronic heart failure.
In agreement with this postulation is the clinical finding that overall sympathetic activity in the body is enhanced in patients with heart failure, despite the fact that their cardiac stores of norepinephrine are reduced ( fig. 3 ). This increased sympathetic activity is reflected in the obvious reduction in cutaneous blood flow,'2 the presence of venoconstriction," 7, 13 the well-documented elevation of renal vascular resistance'4 which can be reduced by sympathetic blockade, and the augmented urinary excretion of norepinephrine. 3 The mechanism responsible for the increased quantities of norepinephrine in the adrenergic nerve endings which can be released by tyramine in patients with heart failure is not clear. However, the recent work of Spector and associates may be relevant; these investigators have provided evidence for the existence of a feedback mechanism which couples the biosynthesis of norepiniephrine to the activity of the rate-limiting biosynthetic enzyme-tyrosine hydroxylase, which in turn is related to the level of sympathetic activity.15' 16 Other studies in our laboratory have shown that the cardiac norepinephrine depletion which occurs in heart failure is accompanied by, and presumably secondary to, a marked reduction in tyrosine hydroxylase activity. 17 Perhaps in the sympathetic neurons innervating the resistance vessels the augmented sympathetic activity occurring in heart failure stimulates production of norepinephrine, while the prolonged, more intense activity in the nerve endings in the heart ultimately reduces the concentration of the rate-limiting biosynthetic enzyme.
